Sialyltransferase 7B inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of sialyltransferase 7B (ST8SIA2), an enzyme responsible for transferring sialic acid residues to glycans on glycoproteins and glycolipids. Sialyltransferase 7B plays a critical role in the process of polysialylation, a specialized form of sialylation where long chains of sialic acid residues are added to proteins, particularly neural cell adhesion molecules (NCAMs). This post-translational modification is essential for modulating cell-cell interactions, neural development, and plasticity, as polysialylation reduces cell adhesion and increases cellular mobility, which is critical during brain development. Inhibitors of sialyltransferase 7B are designed to disrupt this enzymatic process by blocking the enzyme's ability to transfer sialic acids, altering the structure of glycans and their subsequent biological functions.
The development of sialyltransferase 7B inhibitors requires a thorough understanding of the enzyme's active site and the mechanism by which it transfers sialic acids from a donor substrate, CMP-sialic acid, to the acceptor glycan. Techniques such as molecular modeling, X-ray crystallography, and computational docking are used to identify critical regions in the enzyme where inhibitors can bind. These inhibitors are engineered to compete with the natural substrates of sialyltransferase 7B, preventing the enzyme from carrying out its catalytic function. After synthesis, these inhibitors undergo rigorous biochemical testing to assess their binding affinity, specificity, and overall effectiveness in blocking sialyltransferase 7B activity. By inhibiting this enzyme, researchers aim to study the role of polysialylation in cellular processes such as neural development, cell adhesion, and immune modulation. Understanding how sialyltransferase 7B inhibitors impact glycan modification helps reveal the broader implications of sialylation in regulating protein function and cellular behavior.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Zanamivir | 139110-80-8 | sc-208495 | 1 mg | $270.00 | 6 | |
Could inhibit sialyltransferase activity, potentially affecting ST7B-mediated sialylation. | ||||||
Oseltamivir | 196618-13-0 | sc-507283 | 100 g | $324.00 | ||
Might target sialyltransferase activity, possibly inhibiting ST7B function in cellular processes. | ||||||
Lithocholic acid | 434-13-9 | sc-215262 sc-215262A | 10 g 25 g | $100.00 $272.00 | 1 | |
Could influence glycolipid synthesis pathways, possibly affecting ST7B activity. | ||||||
(Z)-Pugnac | 132489-69-1 | sc-204415A sc-204415 | 5 mg 10 mg | $224.00 $380.00 | 3 | |
Might inhibit O-GlcNAcase, potentially influencing glycosylation pathways where ST7B is active. | ||||||
Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside | 3554-93-6 | sc-203427 sc-203427A | 100 mg 1 g | $350.00 $3184.00 | 2 | |
Might inhibit glycosyltransferases, potentially affecting pathways where ST7B is involved. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Could inhibit glycoprotein processing, potentially affecting ST7B-mediated sialylation processes. | ||||||